- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00686322
Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)
Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Lung cancer is a major cause of cancer death in Taiwan and throughout the world in both developed and developing countries. More than 75% of NSCLC patients are inoperable because of either distantly metastatic disease or disease confined to one hemithorax with one or more criteria of unresectability at the time of presentation. The prognosis of such inoperable metastatic patients is poor.
The benefit of adding chemotherapy to radiation therapy for stage III disease of NSCLC is well-established. The largest of the prospective trials was sponsored by the Radiation Therapy Oncology Group (RTOG), ECOG, and the Southwest Oncology Group (SWOG), and allocated 490 patients to receive 2 months of cisplatin + vinblastine chemotherapy followed by 60 Gy of radiation at 2 Gy per fraction; or one of two radiation-alone arms. Overall survival was statistically superior for the patients receiving chemotherapy and radiation versus the other two arms of the study (13.2 months vs 12 months, vs 11.4 months, respectively; p=0.04).
Administration of chemotherapy concurrently with radiation therapy theoretically improves local control by sensitizing the tumor to radiation, while simultaneously treating systemic disease, albeit at the expense of greater local toxicity. Two large phase III studies suggest improvement in both local control and survival with concurrent chemoradiotherapy as compared with sequential chemotherapy followed by radiation for patients with stage III NSCLC. Although rates of nonhematologic toxicity were higher on the concurrent arms, median survival time trended toward superiority in the concomitant chemotherapy plus daily radiation arm compared with the sequential arm.
One source of debate is whether the addition of induction or consolidation chemotherapy adds anything to concomitant chemoradiotherapy, with numerous intergroup trials underway. CALGB has completed a randomized phase II study of two cycles of induction chemotherapy followed by two additional cycles of the same drugs with concomitant radiotherapy. The three treatment arms included four cycles of cisplatin (80 mg/m2) combined with either gemcitabine, paclitaxel, or vinorelbine. Radiotherapy was completed during the last two cycles to a total of 66 Gy. Response rates were similar, and median survival for all patients was 17 months with no clearly superior arm evident in this randomized phase II trial.
We proposed this clinical trial to evaluate the efficacy and toxicity profile of combination chemotherapy with paclitaxel and cisplatin in previously untreated, stage IIIa/IIIb NSCLC patients who received 1 cycle of induction chemotherapy, followed by concurrent chemoradiotherapy, with 2 cycles of consolidation chemotherapy.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Taipei City, Taiwán
- Taipei VGH
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologic or cytological diagnosis of inoperable locally advanced (stage III) NSCLC.
- No prior chemotherapy, immunotherapy, or radiotherapy.
- Performance status of 0 to 2 on the Zubrod scale.
- Clinically measurable disease, defined as bidimensionally measurable lesions with clearly defined margins on x-ray, scan, or physical examination. Lesions serving as measurable disease must be at least 1 cm by 1 cm, as defined by computerized tomography (CT) scan, magnetic resonance imaging (MRI), or chest x-ray.
- Estimated life expectancy of at least 12 weeks.
- Patient compliance and geographic proximity that allow adequate follow-up.
- Adequate bone marrow reserve: white blood cell (WBC) count *4,000/mm3, platelets >100,000/mm3, and hemoglobin *10 g/dL.
- Informed consent from patient.
- Males or females 18 years of age or older.
- If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine contraceptive device [IUD], birth control pills, or barrier device) during and for three months after trial.
Exclusion Criteria:
- Active infection (at the discretion of the investigator).
- Inadequate liver function (total bilirubin >1.5 times above normal range); alanine transaminase (ALT) and aspartate transaminase (AST) greater than 3 times normal (ALT and AST may be elevated to 5 times normal in patients with known metastatic disease in the liver).
- Inadequate renal function (creatinine >2.0 mg/dL).
- Pregnancy or not using appropriate birth control during the study.
- Breast feeding.
- Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)
- Use of any investigational agent in the month before enrollment into the study.
- Patients with leukemia and/or a secondary primary carcinoma except for patients who have had curative therapy to basal cell carcinoma.
- Concomitant myelosuppressive radiotherapy, chemotherapy, hormonal therapy, or immunotherapy will not be allowed except as previously noted for radiation.
- Active cardiac disease requiring therapy for failure, angina, and/or arrhythmias; infarctions within the preceding six months (exception: any patient whose cardiac failure is compensated on medications).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Otro: 1
Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
|
Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
To determine the efficacy of this treatment modality in patients with inoperable stage III NSCLC
Periodo de tiempo: one year
|
one year
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
To determine the toxicity profiles of this treatment modality in patients with inoperable stage III NSCLC
Periodo de tiempo: one year
|
one year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yuh-Min Chen, MD, PhD., Chest Department, Taipei VGH
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Mecanismos moleculares de acción farmacológica
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Agentes antineoplásicos, fitogénicos
- Paclitaxel
- Cisplatino
- Paclitaxel unido a albúmina
Otros números de identificación del estudio
- 97-02-12
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de pulmón de células no pequeñas
-
Adelphi Values LLCBlueprint Medicines CorporationTerminadoLeucemia de mastocitos (LCM) | Mastocitosis Sistémica Agresiva (ASM) | SM w Asoc Clonal Hema Non-mast Cell Linage Disease (SM-AHNMD) | Mastocitosis sistémica latente (MSS) | Mastocitosis Sistémica Indolente (ISM) Subgrupo ISM Completamente ReclutadoEstados Unidos
Ensayos clínicos sobre Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
-
Huazhong University of Science and TechnologyActivo, no reclutandoCáncer gástrico | Cáncer gastroesofágicoPorcelana
-
Washington University School of MedicineReclutamientoCáncer de esófago | Cáncer de esófago | Cáncer de esófagoEstados Unidos
-
City of Hope Medical CenterNational Cancer Institute (NCI)ReclutamientoColangiocarcinoma intrahepático | Carcinoma de vesícula biliar | Colangiocarcinoma intrahepático en estadio IV AJCC v8 | Neoplasia maligna metastásica en el peritoneo | Adenocarcinoma de vías biliares distales | Cáncer de las vías biliares distales en estadio IV AJCC v8 | Cáncer de las vías biliares... y otras condicionesEstados Unidos
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Activo, no reclutandoColangiocarcinoma intrahepático en estadio III AJCC v8 | Colangiocarcinoma intrahepático en estadio IIIA AJCC v8 | Colangiocarcinoma intrahepático en estadio IIIB AJCC v8 | Cáncer de vesícula biliar en estadio III AJCC v8 | Cáncer de vesícula biliar en estadio IIIA AJCC v8 | Cáncer de vesícula... y otras condicionesEstados Unidos
-
University of Southern CaliforniaNational Cancer Institute (NCI); Vasgene Therapeutics, IncTerminadoCáncer de pulmón de células no pequeñas en estadio IIIA | Cáncer de pulmón de células no pequeñas en estadio IIIB | Adenocarcinoma de páncreas | Carcinoma de células escamosas de cabeza y cuello | Carcinoma de pulmón de células no pequeñas recidivante | Cáncer de pulmón de células no pequeñas... y otras condicionesEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoCarcinoma irresecable de vías biliares extrahepáticas | Carcinoma de vesícula biliar irresecable | Cáncer de vesícula biliar en estadio IIIA AJCC v7 | Cáncer de vesícula biliar en estadio IIIB AJCC v7 | Cáncer de vesícula biliar en estadio IVA AJCC v7 | Cáncer de vesícula biliar en estadio IVB... y otras condicionesEstados Unidos
-
Emory UniversityNational Cancer Institute (NCI)RetiradoColangiocarcinoma intrahepático en estadio II AJCC v8 | Colangiocarcinoma intrahepático en estadio III AJCC v8 | Colangiocarcinoma intrahepático resecable | Colangiocarcinoma intrahepático en estadio 0 AJCC v8 | Colangiocarcinoma intrahepático en estadio I AJCC v8Estados Unidos
-
Roswell Park Cancer InstituteNovartisTerminadoNeoplasia sólida maligna avanzada | Adenocarcinoma de páncreas metastásico | Cáncer de páncreas en estadio III | Cáncer de páncreas en estadio IV | ALK positivoEstados Unidos
-
Mayo ClinicNational Cancer Institute (NCI)ReclutamientoCarcinoma de páncreas metastásico | Cáncer de páncreas en estadio IV AJCC v8 | Neoplasia maligna metastásica en el peritoneoEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Activo, no reclutandoAdenocarcinoma de páncreas resecable borderline | Adenocarcinoma ductal pancreático resecable | Adenocarcinoma ductal pancreático localmente avanzadoEstados Unidos